Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.06 and traded as low as C$0.06. Hemostemix shares last traded at C$0.06, with a volume of 19,782 shares.
Hemostemix Stock Performance
The stock has a market capitalization of C$12.30 million, a price-to-earnings ratio of -3.00 and a beta of 0.21. The company’s 50 day moving average is C$0.06 and its 200 day moving average is C$0.07. The company has a debt-to-equity ratio of -66.09, a quick ratio of 0.48 and a current ratio of 0.24.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
